公开(公告)号：US20240400993A1

公开(公告)日：2024-12-05

申请号：US18695720

申请日：2022-09-26

Applicant: Kyoto University ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shin KANEKO ,  Shoichi IRIGUCHI ,  Yoshiaki KASSAI ,  Keiko SEKIYA ,  Atsushi MATSUDA ,  Takayuki SATO

IPC: C12N5/0783 ,  A61K35/17

Abstract: Disclosed is a method for producing regulatory T cells, the method comprising: (1) differentiating cells that can differentiate into regulatory T cells, into which an expression construct is introduced, into regulatory T cells, the expression construct comprising: (a) conserved non-coding sequence (CNS) 1, CNS2, and CNS3 of Foxp3 gene; (b) a promoter; and (c) a nucleic acid encoding FOXP3. Also disclosed are regulatory T cells obtained by the method, and a pharmaceutical composition comprising the regulatory T cells.

公开(公告)号：US20220089672A1

公开(公告)日：2022-03-24

申请号：US17416859

申请日：2019-12-26

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Shin KANEKO ,  Yoshiaki KASSAI ,  Akira HAYASHI

IPC: C07K14/725 ,  C12N15/86

Abstract: The present invention provides a variant of a T-cell receptor containing a combination of two polypeptides containing a constant region of a T cell receptor chain selected from the group consisting of α chain, β chain, γ chain and δ chain, wherein the polypeptide does not contain a complementarity determining region (CDR) of the T cell receptor chain, a complementarity determining region (CDR) of the α chain, and a complementarity determining region (CDR) of the β chain.

公开(公告)号：US20230000915A1

公开(公告)日：2023-01-05

申请号：US17778611

申请日：2020-11-24

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Shin KANEKO ,  Suguru ARIMA ,  Maiko TAKIGUCHI ,  Yoshiaki KASSAI ,  Akira HAYASHI

IPC: A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

Abstract: The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.

公开(公告)号：US20220099670A1

公开(公告)日：2022-03-31

申请号：US17427222

申请日：2021-01-31

Applicant: Kyoto University ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shin KANEKO ,  Shoichi IRIGUCHI ,  Keiko SEKIYA ,  Yoshiaki KASSAI

IPC: G01N33/567 ,  C12N5/00 ,  C12N5/0784 ,  G01N33/50

Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

公开(公告)号：US20230374128A1

公开(公告)日：2023-11-23

申请号：US18030901

申请日：2021-10-08

Applicant: Keio University ,  Takeda Pharmaceutical Company Limited

Inventor： Tsutomu TAKEUCHI ,  Akihiko YOSHIMURA ,  Katsuya SUZUKI ,  Masaru TAKESHITA ,  Marenori KOJIMA ,  Yoshiaki KASSAI ,  Taku KORO ,  Keiko SEKIYA ,  Tomoki YOSHIHARA ,  Ryutaro ADACHI

IPC: C07K16/28 ,  A61P37/06

CPC classification number: C07K16/2803 ,  A61P37/06 ,  A61K2039/505

Abstract: The present invention provides a therapeutic agent for an immune/inflammatory disease comprising an anti-human TIGIT antibody, which activates a suppressive immune checkpoint molecule (TIGIT), as an active ingredient. Also, provided is an antibody having the following characteristics a) and b):



a) the third CDR of heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4
b) the third CDR of light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.

公开(公告)号：US20210381006A1

公开(公告)日：2021-12-09

申请号：US17286334

申请日：2019-10-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu KUWAE ,  Satoru MATSUMOTO ,  Akira HAYASHI ,  Yoshiaki KASSAI ,  Kazuhide NAKAYAMA

IPC: C12N15/88 ,  A61K35/17 ,  A61K9/127 ,  C07K16/28

Abstract: The present invention provides a method for activating/proliferating T cells, including a step of contacting a cell population containing T cells with a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface, and a method for delivering a nucleic acid into T cells, the methods including a step of contacting a cell population containing T cells simultaneously with (a) a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface and containing a nucleic acid inside, or (b) at least one kind of T cell activating ligand, and a nucleic acid delivery carrier containing a nucleic acid inside and free of a T cell activating ligand added to its surface, a method for producing a medicament containing T cells and the like.